T he natural history of vancomycin-resistant enterococcus (VRE) infection is such that VRE colonization, predominantly of the gastrointestinal tract, typically precedes infection. At Mayo Medical Center (Rochester, MN), routine aerobic bacterial throat, rectal, wound, biliary, and urinary surveillance cultures have been collected from liver transplant recipients as part of a selective bowel antibiotic decontamination program for liver transplant patients. Beginning in 1995, as a result of these surveillance cultures, VRE colonization was identified in liver and kidney transplant patients. The purpose of this study is to describe the natural history of VRE colonization in liver and kidney transplant patients.
Methods
Cultures for VRERoutine surveillance aerobic bacterial throat, rectal, wound, biliary, and urinary cultures have been collected from hospitalized liver transplant recipients as part of a selective bowel decontamination program for liver transplant patients since the inception of the liver transplant program at Mayo Medical Center in 1985. Surveillance cultures were originally obtained twice weekly for 1 week posttransplantation and then weekly until selective bowel decontamination was discontinued (ϳ3 weeks). Through these surveillance cultures, VRE colonization was detected in the liver transplant population.Beginning November 1995, admission and twice-weekly rectal surveillance cultures were collected from all patients admitted to the adult liver, kidney, and kidney/pancreas transplant unit. These specimens were cultured on primary sheep blood agar or subculture of enriched brain heart infusion broth to Columbia colistin-nalidixic acid (CNA) agar. Subsequent to the identification of the first patient with VRE colonization, some of these cultures were ordered as "VRE screens" and cultured on selective media, as follows. Beginning October 1995, in-house CNA agar with 16 g/mL of vancomycin was used. In June 1996, Enterococcosel agar with 8 g/mL of vancomycin (Becton Dickinson, Cockeysville, MD) was substituted. The study period extended from 1985 through December 1997.
Selective Bowel DecontaminationSelective bowel decontamination was performed using a mixture of 80 mg of gentamicin, 100 mg of polymyxin E, and 2 million U of nystatin administered orally or by nasogastric tube 4 times daily, beginning at least 2 days before liver transplantation and discontinued at the time of discharge from the initial hospitalization. This regimen was resumed when patients were rehospitalized. Orabase paste (Colgate, Surgery, ‡Hepatology, and §Clinical Microbiology, Mayo Clinic and Foundation, Rochester, MN; and ʈCorixa Corporation,
From the *Divisions of Infectious Diseases, †Transplantation